Literature DB >> 9672256

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter.

Y He1, Q Zeng, S D Drenning, M F Melhem, D J Tweardy, L Huang, J R Grandis.   

Abstract

BACKGROUND: Squamous cell carcinomas of the head and neck (SCCHN), unlike normal mucosal squamous epithelial cells, overexpress epidermal growth factor receptor (EGFR) messenger RNA and protein. EGFR protein is required to sustain the proliferation of SCCHN cells in vitro. To determine whether EGFR expression contributes to tumor growth, we investigated the effect of suppressing EGFR expression in tumor xenografts through in situ expression of antisense oligonucleotides.
METHODS: Intratumoral cationic liposome-mediated gene transfer was used to deliver plasmids capable of expressing sense or antisense EGFR sequences into human head and neck tumors, which were grown as subcutaneous xenografts in nude mice. The oligonucleotides were expressed under the control of the U6 RNA promoter.
RESULTS: Direct inoculation of the EGFR antisense (but not the corresponding sense) plasmid construct into established SCCHN xenografts resulted in inhibition of tumor growth, suppression of EGFR protein expression, and an increased rate of apoptosis (programmed cell death). Sustained antitumor effects were observed for up to 2 weeks after the treatments were discontinued.
CONCLUSION: These results suggest that interference with EGFR expression, using an antisense-based gene therapy approach, may be an effective means of treating EGFR-overexpressing tumors, including SCCHN.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672256     DOI: 10.1093/jnci/90.14.1080

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  27 in total

Review 1.  Molecular therapy in head and neck oncology.

Authors:  Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

Review 2.  Targeted therapy in head and neck cancer.

Authors:  S K Kundu; M Nestor
Journal:  Tumour Biol       Date:  2012-02-29

Review 3.  An update on epidermal growth factor receptor inhibitors.

Authors:  Shanu Modi; Andrew D Seidman
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

4.  Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.

Authors:  H Swaisland; A Laight; L Stafford; H Jones; C Morris; A Dane; R Yates
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy.

Authors:  Andrew R Carson; Charles F McTiernan; Linda Lavery; Michelle Grata; Xiaoping Leng; Jianjun Wang; Xucai Chen; Flordeliza S Villanueva
Journal:  Cancer Res       Date:  2012-09-25       Impact factor: 12.701

6.  Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Authors:  Andre Cassell; Maria L Freilino; Jessica Lee; Sharon Barr; Lin Wang; Mary C Panahandeh; Sufi M Thomas; Jennifer R Grandis
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

Review 8.  Mechanisms of resistance to EGFR targeted therapies.

Authors:  Gorjan Hrustanovic; Bianca J Lee; Trever G Bivona
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 9.  Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.

Authors:  Ann Marie Egloff; Jennifer R Grandis
Journal:  Semin Oncol       Date:  2008-06       Impact factor: 4.929

10.  Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.

Authors:  Stephen Y Lai; Priya Koppikar; Sufi M Thomas; Erin E Childs; Ann Marie Egloff; Raja R Seethala; Barton F Branstetter; William E Gooding; Ashok Muthukrishnan; James M Mountz; Vivian W Y Lui; Dong M Shin; Sanjiv S Agarwala; Rita Johnson; Larry A Couture; Eugene N Myers; Jonas T Johnson; Gordon Mills; Athanassios Argiris; Jennifer R Grandis
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.